News
AHA: One dose of Lilly’s siRNA drug cuts Lp(a) for a year
A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular